{"gene":"FLT3","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1993,"finding":"FLT3/FLK2 receptor tyrosine kinase has intrinsic tyrosine kinase activity; a point mutation in the conserved phosphoryltransferase domain inactivates catalytic function; a chimeric CSF-1R extracellular domain/FLT3 kinase domain construct demonstrated transforming activity (anchorage-independent growth) upon CSF-1 stimulation, establishing ligand-induced kinase activation as the mechanism of transformation.","method":"Site-directed mutagenesis of kinase domain, chimeric receptor construct expressed in COS-1 cells, anchorage-independent growth assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with active-site mutagenesis and chimeric receptor reconstitution, single lab with two orthogonal functional methods","pmids":["8384358"],"is_preprint":false},{"year":1993,"finding":"FLT3 protein undergoes N-linked glycosylation maturation: a 143 kDa high-mannose form is processed to a 158 kDa complex-carbohydrate form that is expressed on the cell surface. FLT3 is heavily phosphorylated on tyrosine even in the absence of ligand, resembling c-ErbB2.","method":"Immunoprecipitation with polyclonal antibodies, pulse-chase analysis in COS-7 transfectants, N-glycosidase F digestion, cell-surface labeling","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical reconstitution with multiple orthogonal methods (pulse-chase, glycosidase digestion, surface labeling) in a single rigorous study","pmids":["7681159"],"is_preprint":false},{"year":1993,"finding":"Activated FLT3/FLK2 kinase recruits and/or phosphorylates phospholipase C-γ1, Ras-GAP, PI3K p85 subunit, Shc, Grb2, Vav, Fyn, and Src. Physical association with the FLT3 cytoplasmic domain was demonstrated for PLC-γ1, PI3K p85, Shc, Grb2, and Src family kinases, but not for Ras-GAP, Vav, or Nck. Cell-type-specific differences in tyrosine phosphorylation of p85 and Shc were observed.","method":"Chimeric CSF-1R/FLK2 receptor in NIH 3T3 and Ba/F3 cells, co-immunoprecipitation, tyrosine phosphorylation assays, factor-independence assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstituted chimeric receptor system with reciprocal co-IP and functional readouts (mitogenesis, IL-3 independence), multiple substrates tested","pmids":["7692230"],"is_preprint":false},{"year":1994,"finding":"FLT3 ligand (FL) was purified to homogeneity from mouse thymic stromal cells, partially sequenced, and shown to be encoded by multiple cDNA variants; some contain transmembrane segments indicating a membrane-bound precursor requiring proteolytic processing to release soluble ligand. FL synergizes with IL-3, IL-6, and GM-CSF to stimulate mouse stem cells and a primitive human progenitor population.","method":"Protein purification, partial sequencing, cDNA cloning, functional proliferation assays with purified ligand","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — ligand purified to homogeneity, sequenced, cDNAs cloned, and functional activity confirmed; foundational biochemical characterization","pmids":["8145851"],"is_preprint":false},{"year":1995,"finding":"Mice with targeted disruption of flk2/flt3 are viable and healthy but have specific deficiencies in primitive B lymphoid progenitors. Bone marrow transplantation revealed further deficiency in T cell and myeloid reconstitution by mutant stem cells. Double knockout of c-kit and flk2 produced severe reductions in hematopoietic cell numbers and postnatal lethality, establishing genetic epistasis between FLT3 and c-KIT in multipotent progenitor maintenance.","method":"Gene targeting (knockout mice), bone marrow transplantation, flow cytometric analysis of hematopoietic populations","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function knockout with defined cellular phenotype; genetic epistasis established via double-knockout; replicated across multiple assays","pmids":["7621074"],"is_preprint":false},{"year":1996,"finding":"Monoclonal antibodies against the FLT3 extracellular domain can mimic FL activity, activating and modulating the receptor, establishing that the extracellular domain is sufficient for receptor activation. FLT3 surface expression is restricted to CD34+ hematopoietic progenitors and leukemic blasts; most CD34+FLT3+ cells co-express CD117 (KIT).","method":"Monoclonal antibody generation, functional receptor activation assays, flow cytometry (3-color analysis)","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional agonist antibody assay plus direct surface phenotyping; single lab, two orthogonal approaches","pmids":["8637232"],"is_preprint":false},{"year":1996,"finding":"Stimulation of leukemic patient samples with FLT3 ligand results in autophosphorylation of the FLT3 receptor, confirming that overexpressed FLT3 in AML cells is functional and capable of ligand-induced kinase activation.","method":"Western blotting with anti-FLT3 antisera, FLT3 ligand stimulation and autophosphorylation assay in primary leukemic bone marrow samples","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct autophosphorylation assay on primary patient samples; single lab, functional readout","pmids":["8562934"],"is_preprint":false},{"year":1996,"finding":"PI3K binds to a unique site in the carboxy tail of murine FLT3/FLK2; however, mutant receptors unable to couple to PI3K retain full mitogenic signaling and normal receptor down-regulation in NIH 3T3 fibroblasts and Ba/F3 cells, demonstrating that PI3K is not required for FLT3-mediated mitogenesis or receptor internalization.","method":"Mutagenesis of PI3K binding site, transfection into NIH 3T3 and Ba/F3 cells, proliferation assays, receptor down-regulation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis with functional reconstitution in two cell types; single lab, multiple orthogonal methods; rigorous negative result","pmids":["8702727"],"is_preprint":false},{"year":2002,"finding":"FLT3 internal tandem duplication (ITD) mutations in the juxtamembrane domain result in constitutive, ligand-independent tyrosine kinase activation. FLT3-ITD confers factor-independent growth to Ba/F3 and 32D cells, activates STAT, RAS/MAPK, and PI3K/AKT pathways, and causes a myeloproliferative disorder upon retroviral transduction into primary murine bone marrow. Mutations that abrogate kinase activity abolish transforming properties.","method":"Retroviral transduction into Ba/F3 and 32D cells, factor-independence assay, signaling pathway analysis, murine bone marrow transduction/transplantation model, kinase-dead mutagenesis","journal":"Current opinion in hematology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (cell transformation, in vivo mouse model, kinase-dead mutant) reported across multiple labs","pmids":["12042700"],"is_preprint":false},{"year":2005,"finding":"Oncogenic FLT3 mutations (ITD and TKD point mutations) result in constitutive activation of downstream pathways shared with wild-type FLT3 (PI3K, Src kinases, MAPK) but additionally cause aberrant strong activation of STAT5 and induction of STAT5 target genes, as well as repression of myeloid transcription factors C/EBPβ and PU.1, which are not activated by wild-type receptor.","method":"Signal transduction analysis in cell lines expressing wild-type vs. mutant FLT3, immunoprecipitation, reporter assays, gene expression analysis","journal":"International journal of hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-line-based signaling comparison; single review synthesizing experimental data from multiple labs","pmids":["16146838"],"is_preprint":false},{"year":2011,"finding":"Lineage tracing using a Flk2-Cre mouse model demonstrated that all mature hematopoietic lineages—including megakaryocyte/erythroid cells—pass through a Flk2-expressing non-self-renewing progenitor stage during steady-state hematopoiesis, after irradiation stress, and upon HSC transplantation. HSC origin and maintenance do not include a Flk2+ stage, dissociating HSC self-renewal from Flk2 expression.","method":"In vivo lineage tracing (Flk2-Cre × Rosa26-reporter mice), flow cytometry of all hematopoietic lineages, bone marrow transplantation","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic fate mapping with multiple conditions tested (steady-state, stress, transplant) provides definitive pathway position; replicated across experimental contexts","pmids":["21726834"],"is_preprint":false},{"year":2013,"finding":"Flk2/FLT3 is critical for proliferative expansion of multipotent progenitors common to all lymphoid and myeloid lineages; Flk2 deficiency impairs generation of both lymphoid and myeloid progenitors by abrogating propagation of their common upstream precursor without affecting lineage choice. FLT3-ITD failed to transform primary hematopoietic progenitors from Cdk6-/- mice, and FLT3-ITD signaling upregulates CDK6 through the SRC-family kinase HCK, establishing an FLT3/HCK/CDK6 pathway.","method":"Flk2 knockout mice, transplantation of purified progenitors, lineage analysis; separate pathway study using Cdk6-/- mice and HCK inhibition in FLT3-ITD AML cells","journal":"Experimental hematology; Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout combined with progenitor transplantation; epistasis established by Cdk6-/- rescue experiment; two separate papers","pmids":["24333663","27323399"],"is_preprint":false},{"year":2017,"finding":"FLT3 and FLT3-ITD directly bind and phosphorylate the CDK inhibitor p27Kip1 at tyrosine residue 88, inactivating its cell-cycle inhibitory function. Inhibition of FLT3-ITD kinase reduced p27-Y88 phosphorylation and caused cell cycle arrest. Phospho-Y88-p27 was detected in primary AML patient samples.","method":"Co-immunoprecipitation of FLT3 and p27, in vitro phosphorylation assay, FLT3 inhibitor (AC220) treatment in cell lines and primary AML patient samples, flow cytometry for cell cycle","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct in vitro kinase assay demonstrating substrate phosphorylation, confirmed by co-IP and validated in primary patient samples; single lab with multiple orthogonal methods","pmids":["28522571"],"is_preprint":false},{"year":2019,"finding":"PRMT1 methylates FLT3-ITD protein at arginine residues 972/973, promoting AML maintenance. This methylation occurs independently of FLT3 kinase activity and persists following FLT3 kinase inhibition. FLT3-ITD methylation cross-talks with phosphorylation at tyrosine 969. Genetic or pharmacological PRMT1 inhibition blocked FLT3-ITD+ AML cell maintenance.","method":"Co-immunoprecipitation, genome-wide analysis, PRMT1 knockout mouse studies, mass spectrometry, site-directed mutagenesis, patient-derived xenograft models","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — identification of PTM writer (PRMT1), specific methylation sites by MS, functional validation with mutagenesis and in vivo xenograft model; multiple orthogonal methods","pmids":["31217189"],"is_preprint":false},{"year":2021,"finding":"FLT3-ITD is S-palmitoylated by the palmitoyl acyltransferase ZDHHC6, which retains FLT3-ITD in the endoplasmic reticulum and restricts signaling to constitutive STAT5 phosphorylation. Disruption of palmitoylation redirects FLT3-ITD to the plasma membrane, rewiring downstream signaling to additionally activate AKT and ERK pathways, and exacerbates leukemia progression in xenotransplant models.","method":"Palmitoylation assay, ZDHHC6 knockdown/overexpression, subcellular fractionation, signaling analysis, xenotransplant mouse models, primary AML patient samples","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — identification of palmitoylation writer (ZDHHC6), functional consequence on subcellular localization and signaling rewiring, validated in vivo and in primary patient samples","pmids":["34111291"],"is_preprint":false},{"year":2021,"finding":"FLT3 TKI (gilteritinib/sorafenib) treatment dissociates BIM from MCL-1 but increases BIM-BCL-2 binding. Combined FLT3 TKI + venetoclax (BCL-2 inhibitor) treatment dissociates BIM from both BCL-2 and MCL-1 and increases BIM-BAX binding, driving apoptosis. This mechanistic cross-talk establishes a pro-survival role of BCL-2 as a BIM reservoir following FLT3 inhibition.","method":"Co-immunoprecipitation of BIM with BCL-2/MCL-1/BAX, proliferation assays, apoptosis assays in FLT3-ITD cell lines and primary AML samples","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP of multiple BCL-2 family members, functional apoptosis readouts in cell lines and primary samples; single lab, multiple orthogonal methods","pmids":["34024909"],"is_preprint":false},{"year":2016,"finding":"DOCK2, a guanine nucleotide exchange factor for Rho GTPases, co-immunoprecipitates with both wild-type FLT3 and FLT3-ITD in leukemia cells. DOCK2 knockdown selectively reduces proliferation and colony formation in FLT3-overactive leukemia cells and sensitizes them to cytarabine and FLT3 inhibitors; prolonged survival in a mouse xenograft model was observed.","method":"Mass spectrometry-based protein interaction screen, co-immunoprecipitation, shRNA knockdown, proliferation/colony assays, mouse xenograft model","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-identified interaction confirmed by co-IP; functional validation by KD with in vitro and in vivo phenotypes; single lab","pmids":["27748370"],"is_preprint":false},{"year":2013,"finding":"The transcription factors MYB and C/EBPα directly regulate FLT3 expression: MYB binds the FLT3 promoter and C/EBPα binds an intronic regulatory module, as demonstrated by chromatin accessibility assays and epigenetic markings in murine AML cells and primary human AML patient samples.","method":"Chromatin accessibility assays, chromatin immunoprecipitation (ChIP), epigenetic histone mark analysis, gene expression profiling in AML patient samples","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating in vivo binding of MYB and C/EBPα to FLT3 regulatory elements; validated in primary human AML; single lab","pmids":["23340802"],"is_preprint":false},{"year":2017,"finding":"FLT3-ITD directly impacts RUNX1 activity by upregulating and phosphorylating RUNX1, which then cooperates with FLT3-ITD to induce AML. Inactivating RUNX1 in FLT3-ITD tumors releases differentiation block and downregulates ribosome biogenesis genes. HHEX was identified as a direct RUNX1 and FLT3-ITD target gene that can substitute for RUNX1 in cooperating with FLT3-ITD.","method":"Genetic co-expression experiments in primary hematopoietic progenitors, RUNX1 inactivation, gene expression analysis, ChIP, murine AML model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — epistasis established by RUNX1 inactivation in FLT3-ITD tumors with defined phenotypic readouts; ChIP identifies direct target; in vivo model; single lab with multiple orthogonal methods","pmids":["28213513"],"is_preprint":false},{"year":2018,"finding":"Ligand-induced FLT3 dimerization and autophosphorylation creates binding sites for SRC family kinases (SFKs), which are recruited to specific phosphotyrosine residues on FLT3. SFKs regulate downstream RAS/ERK signaling through GAB2 and SHC adaptor proteins, and negatively regulate FLT3 signaling through phosphorylation of the ubiquitin E3 ligase CBL. Individual SFK members have distinct positive vs. negative signaling roles downstream of FLT3.","method":"Co-immunoprecipitation, phosphorylation assays, SFK knockdown/inhibition studies, signaling pathway analysis","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — review synthesizing experimental co-IP and functional data from multiple studies; mechanistic roles of individual SFKs established across labs","pmids":["30552988"],"is_preprint":false},{"year":2020,"finding":"A low-frequency intronic FLT3 variant (rs76428106-C) generates a cryptic splice site introducing a stop codon in 30% of transcripts, predicted to encode a truncated protein lacking tyrosine kinase domains (loss-of-function). Each copy of this variant doubles plasma FLT3 ligand levels, demonstrating a compensatory feedback mechanism where reduced FLT3 receptor function elevates ligand.","method":"RNA sequencing to identify cryptic splice site, GWAS, plasma FLT3 ligand quantification by ELISA","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — RNA sequencing directly demonstrates aberrant splicing; ELISA quantifies compensatory ligand elevation; large-scale human genetics study with functional validation","pmids":["32581359"],"is_preprint":false},{"year":2005,"finding":"FLT3-ITD mutations activate tyrosine kinase through receptor dimerization in a FLT3 ligand-independent manner, contributing to a block in myeloid differentiation in addition to proliferative and anti-apoptotic signaling. FLT3 tyrosine kinase inhibitors suppress growth and induce apoptosis and differentiation of FLT3-ITD-expressing leukemia cells.","method":"Cell line studies with FLT3-ITD expression, differentiation assays, apoptosis assays, TKI treatment experiments","journal":"Leukemia & lymphoma","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell-line data demonstrating differentiation block and its reversal by kinase inhibition; mechanism of ITD-induced dimerization established","pmids":["16263569"],"is_preprint":false}],"current_model":"FLT3 is a class III receptor tyrosine kinase expressed on primitive hematopoietic progenitors that, upon binding its transmembrane/soluble ligand FL, dimerizes and autophosphorylates, recruiting signal transducers including PLC-γ1, PI3K p85, Shc, Grb2, and SRC family kinases (which in turn regulate RAS/ERK via GAB2/SHC and negatively regulate FLT3 via CBL), while activating STAT, RAS/MAPK, and PI3K/AKT pathways to drive proliferation, survival, and differentiation of hematopoietic progenitors through a obligate Flk2+ intermediate stage; oncogenic FLT3-ITD mutations cause ligand-independent kinase activation through juxtamembrane dimerization, aberrantly strong STAT5 activation, repression of myeloid transcription factors, and phosphorylation/inactivation of the CDK inhibitor p27Kip1, while its subcellular localization and signaling are controlled post-translationally by ZDHHC6-mediated S-palmitoylation (retaining ITD in the ER for STAT5 signaling) and PRMT1-mediated arginine methylation at R972/973 (independently of kinase activity)."},"narrative":{"mechanistic_narrative":"FLT3 (FLK2) is a class III receptor tyrosine kinase expressed on CD34+ hematopoietic progenitors and leukemic blasts that drives proliferative expansion and survival of multipotent and lineage-restricted progenitors [PMID:8384358, PMID:8637232, PMID:31217189]. Its ligand FL, produced as a membrane-bound precursor that is proteolytically processed to a soluble form, synergizes with IL-3, IL-6, and GM-CSF to stimulate stem and primitive progenitor populations [PMID:8145851]; ligand engagement of the extracellular domain induces receptor dimerization and autophosphorylation, and agonist antibodies against the ectodomain are sufficient to mimic this activation [PMID:8384358, PMID:8637232]. The mature, complex-glycosylated receptor recruits and phosphorylates PLC-γ1, PI3K p85, Shc, Grb2, and SRC-family kinases at specific phosphotyrosine sites, with SFKs routing RAS/ERK signaling through GAB2/SHC and providing negative feedback via the E3 ligase CBL, while PI3K coupling is dispensable for mitogenesis and receptor internalization [PMID:7681159, PMID:7692230, PMID:8702727, PMID:30552988]. During development FLT3 is genetically required for propagation of a common lymphoid/myeloid progenitor and acts in epistasis with c-KIT in multipotent progenitor maintenance; fate mapping places a non-self-renewing Flk2+ stage on the path to all mature lineages while excluding it from HSC self-renewal [PMID:7621074, PMID:21726834, PMID:31217189]. Internal tandem duplication (ITD) mutations in the juxtamembrane domain cause ligand-independent, dimerization-driven constitutive kinase activation that confers factor-independent growth and a myeloproliferative disorder, signaling through PI3K/AKT, RAS/MAPK and aberrantly strong STAT5 while repressing myeloid transcription factors C/EBPβ and PU.1 to block differentiation [PMID:12042700, PMID:16146838, PMID:16263569]. Oncogenic FLT3 additionally phosphorylates the CDK inhibitor p27Kip1 at Y88 to neutralize cell-cycle inhibition, drives an HCK/CDK6 proliferative axis, and cooperates with phosphorylated RUNX1 (and its target HHEX) to enforce the differentiation block [PMID:28522571, PMID:31217189, PMID:28213513]. FLT3-ITD localization and signaling are tuned post-translationally: ZDHHC6-mediated S-palmitoylation retains the receptor in the ER and restricts output to constitutive STAT5, whereas loss of palmitoylation redirects it to the plasma membrane and rewires signaling to AKT/ERK, and PRMT1-mediated arginine methylation at R972/973 supports AML maintenance independently of kinase activity [PMID:31217189, PMID:34111291]. FLT3 expression is set by MYB binding its promoter and C/EBPα binding an intronic module [PMID:23340802].","teleology":[{"year":1993,"claim":"Established that FLT3 is a functional tyrosine kinase whose ligand-induced catalytic activation is the basis of cellular transformation, defining the receptor's core enzymatic mechanism.","evidence":"Active-site mutagenesis and a CSF-1R/FLT3 chimeric receptor scored by anchorage-independent growth in COS-1 cells","pmids":["8384358"],"confidence":"High","gaps":["Native ligand not yet identified","Downstream effectors undefined"]},{"year":1993,"claim":"Defined FLT3 as a glycosylated cell-surface receptor maturing from a high-mannose to a complex-carbohydrate form, linking glycan processing to surface display.","evidence":"Pulse-chase, N-glycosidase F digestion and cell-surface labeling of COS-7 transfectants","pmids":["7681159"],"confidence":"High","gaps":["Functional significance of ligand-independent tyrosine phosphorylation unclear","No structural model of the receptor"]},{"year":1993,"claim":"Identified the proximal signal transducers physically recruited to the activated receptor, mapping the immediate signaling complex.","evidence":"Chimeric CSF-1R/FLK2 receptor with reciprocal co-IP and mitogenesis/IL-3-independence readouts in NIH 3T3 and Ba/F3 cells","pmids":["7692230"],"confidence":"High","gaps":["Relative contribution of each effector to proliferation not resolved","Cell-type differences in p85/Shc phosphorylation unexplained"]},{"year":1994,"claim":"Purified and cloned the FLT3 ligand, establishing that a membrane-bound precursor is processed to a soluble cytokine that synergizes with other factors on stem/progenitor cells.","evidence":"Protein purification to homogeneity, partial sequencing, cDNA cloning and proliferation assays from mouse thymic stroma","pmids":["8145851"],"confidence":"High","gaps":["Protease responsible for shedding not identified","Stoichiometry of ligand-receptor dimerization not defined"]},{"year":1995,"claim":"Assigned FLT3 a physiological role in hematopoiesis and placed it genetically alongside c-KIT, distinguishing in vivo function from cell-line biochemistry.","evidence":"Flk2/flt3 knockout and flk2/c-kit double-knockout mice with bone marrow transplantation and lineage flow cytometry","pmids":["7621074"],"confidence":"High","gaps":["Molecular basis of B-lineage selectivity unclear","Mechanism of KIT epistasis not defined at the signaling level"]},{"year":1996,"claim":"Showed the extracellular domain alone is sufficient for activation and mapped FLT3 surface expression to CD34+ progenitors and leukemic blasts, tying the receptor to leukemia-relevant cells.","evidence":"Agonist monoclonal antibodies and 3-color flow cytometry","pmids":["8637232"],"confidence":"Medium","gaps":["Single-lab antibody mimicry","Quantitative comparison to native ligand activation lacking"]},{"year":1996,"claim":"Demonstrated that FLT3 overexpressed on primary AML blasts is functional and ligand-responsive, validating the receptor as active in patient disease.","evidence":"FL stimulation and anti-FLT3 immunoblot autophosphorylation assays on primary leukemic marrow","pmids":["8562934"],"confidence":"Medium","gaps":["Does not establish causal role in leukemogenesis","Downstream consequences in blasts not measured"]},{"year":1996,"claim":"Used loss-of-coupling mutagenesis to show PI3K is dispensable for FLT3 mitogenesis and internalization, refining which effectors are essential versus auxiliary.","evidence":"PI3K-binding-site mutants in NIH 3T3 and Ba/F3 cells with proliferation and down-regulation assays","pmids":["8702727"],"confidence":"High","gaps":["PI3K function in other cell contexts not excluded","Compensating effectors not identified"]},{"year":2002,"claim":"Defined the oncogenic ITD mechanism: juxtamembrane duplications cause ligand-independent constitutive kinase activation that transforms cells and causes myeloproliferative disease in vivo, linking a specific mutation to leukemia.","evidence":"Retroviral ITD transduction of Ba/F3, 32D and primary murine marrow with factor-independence, signaling analysis, transplantation and kinase-dead controls","pmids":["12042700"],"confidence":"High","gaps":["Quantitative difference in signaling vs wild-type not yet detailed","Mechanism of ligand-independent dimerization not structurally defined"]},{"year":2005,"claim":"Distinguished oncogenic from physiological signaling by showing mutant FLT3 aberrantly activates STAT5 and represses myeloid transcription factors, and that ITD-driven dimerization blocks differentiation reversibly by TKI.","evidence":"Comparative signaling, reporter and gene-expression analysis in wild-type vs mutant FLT3 cell lines; differentiation/apoptosis assays under TKI","pmids":["16146838","16263569"],"confidence":"Medium","gaps":["Direct STAT5 target genes in primary cells incompletely mapped","Mechanism of C/EBPβ/PU.1 repression not resolved"]},{"year":2011,"claim":"Resolved FLT3's exact position in the hematopoietic hierarchy, showing all mature lineages transit a Flk2+ non-self-renewing stage that is excluded from HSC self-renewal.","evidence":"Flk2-Cre x Rosa26 in vivo lineage tracing across steady-state, stress and transplant conditions","pmids":["21726834"],"confidence":"High","gaps":["Does not address whether FLT3 signaling instructs lineage transitions","Megakaryocyte/erythroid routing details limited"]},{"year":2013,"claim":"Established FLT3 as required for proliferative expansion of a common multipotent progenitor and identified an FLT3/HCK/CDK6 axis required for ITD transformation, connecting the receptor to cell-cycle machinery.","evidence":"Flk2 knockout with purified-progenitor transplantation; Cdk6-/- rescue and HCK inhibition in FLT3-ITD AML cells","pmids":["24333663","27323399"],"confidence":"Medium","gaps":["How HCK selectively upregulates CDK6 not mechanistically detailed","Two separate studies not jointly validated"]},{"year":2013,"claim":"Defined the transcriptional control of FLT3 itself, identifying MYB and C/EBPα as direct regulators binding promoter and intronic elements.","evidence":"Chromatin accessibility, ChIP and histone-mark analysis in murine AML and primary human AML","pmids":["23340802"],"confidence":"Medium","gaps":["Single lab","Functional impact of each element on FLT3 dosage not quantified"]},{"year":2017,"claim":"Identified p27Kip1-Y88 as a direct FLT3 substrate, providing a kinase-to-cell-cycle link by which the receptor inactivates a CDK inhibitor.","evidence":"Co-IP, in vitro kinase assay and AC220 treatment in cell lines and primary AML samples","pmids":["28522571"],"confidence":"High","gaps":["Contribution relative to STAT5/CDK6 routes not quantified","Structural basis of p27 recognition unknown"]},{"year":2017,"claim":"Showed FLT3-ITD cooperates with phosphorylated RUNX1 (and its target HHEX) to enforce differentiation block and ribosome biogenesis, defining a transcriptional cooperator of the oncogene.","evidence":"Co-expression, RUNX1 inactivation, ChIP and gene-expression analysis in a murine AML model","pmids":["28213513"],"confidence":"High","gaps":["Direct biochemical RUNX1 phosphorylation by FLT3 not isolated","Generality across AML subtypes untested"]},{"year":2018,"claim":"Detailed the SRC-family kinase node downstream of FLT3, showing SFKs route RAS/ERK via GAB2/SHC while negatively feeding back through CBL, with member-specific roles.","evidence":"Co-IP, phosphorylation and SFK knockdown/inhibition studies synthesized in a review","pmids":["30552988"],"confidence":"Medium","gaps":["Individual SFK assignments rest on aggregated data","In vivo relevance of CBL feedback in AML not quantified"]},{"year":2019,"claim":"Established arginine methylation as a kinase-independent regulatory layer, identifying PRMT1 as the writer at R972/973 required for FLT3-ITD AML maintenance.","evidence":"Co-IP, mass spectrometry, site-directed mutagenesis, PRMT1 knockout and PDX models","pmids":["31217189"],"confidence":"High","gaps":["Reader of the methyl mark not identified","Mechanism of cross-talk with Y969 phosphorylation incompletely defined"]},{"year":2020,"claim":"Revealed a population-level feedback loop in which a loss-of-function FLT3 splice variant doubles plasma FL, showing receptor function reciprocally sets ligand levels in humans.","evidence":"RNA-seq identification of a cryptic splice site, GWAS and plasma FL ELISA","pmids":["32581359"],"confidence":"High","gaps":["Cellular source of compensatory ligand not localized","Physiological consequence of the truncated protein unmeasured"]},{"year":2021,"claim":"Defined S-palmitoylation by ZDHHC6 as a localization switch confining FLT3-ITD to the ER and restricting output to STAT5, with loss redirecting it to the plasma membrane and rewiring to AKT/ERK.","evidence":"Palmitoylation assay, ZDHHC6 knockdown/overexpression, fractionation, signaling analysis and xenotransplant models with primary AML samples","pmids":["34111291"],"confidence":"High","gaps":["Depalmitoylase counter-enzyme not identified","Therapeutic exploitability not established"]},{"year":2021,"claim":"Mapped a BCL-2-family rewiring after FLT3 inhibition in which BCL-2 sequesters BIM, providing a mechanistic rationale for combining FLT3 TKI with venetoclax.","evidence":"Reciprocal co-IP of BIM with BCL-2/MCL-1/BAX and apoptosis assays in FLT3-ITD cell lines and primary AML","pmids":["34024909"],"confidence":"High","gaps":["Transcriptional vs post-translational basis of BIM shift not separated","Clinical durability not addressed by mechanism"]},{"year":2016,"claim":"Identified DOCK2 as a FLT3-associated Rho-GEF required for proliferation of FLT3-overactive leukemia and modulating TKI/cytarabine sensitivity, expanding the FLT3 interactome.","evidence":"MS interaction screen, co-IP, shRNA knockdown with proliferation/colony assays and xenograft survival","pmids":["27748370"],"confidence":"Medium","gaps":["Directness of FLT3-DOCK2 binding vs complex association not resolved","Rho-GTPase effector downstream of DOCK2 not defined"]},{"year":null,"claim":"How the distinct post-translational layers (palmitoylation, arginine methylation, phosphorylation) and transcriptional cooperators are integrated to select STAT5 versus AKT/ERK outputs and enforce differentiation block remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model linking localization, PTMs and effector choice","Readers/erasers of methyl and acyl marks not fully identified","Structural basis of ITD-driven ligand-independent dimerization undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,12]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,12]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,5]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[3,5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,5,14]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,8,9,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,13,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,10,13]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,13,14]}],"complexes":[],"partners":["FLT3LG","PLCG1","PIK3R1","SHC1","GRB2","CBL","DOCK2","PRMT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P36888","full_name":"Receptor-type tyrosine-protein kinase FLT3","aliases":["FL cytokine receptor","Fetal liver kinase-2","FLK-2","Fms-like tyrosine kinase 3","FLT-3","Stem cell tyrosine kinase 1","STK-1"],"length_aa":993,"mass_kda":112.9,"function":"Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways","subcellular_location":"Membrane; Endoplasmic reticulum lumen","url":"https://www.uniprot.org/uniprotkb/P36888/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FLT3","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FLT3","total_profiled":1310},"omim":[{"mim_id":"618308","title":"NOP9 NUCLEOLAR PROTEIN; NOP9","url":"https://www.omim.org/entry/618308"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"612990","title":"ASXL TRANSCRIPTIONAL REGULATOR 1; ASXL1","url":"https://www.omim.org/entry/612990"},{"mim_id":"612176","title":"MYB-LIKE, SWIRM, AND MPN DOMAINS-CONTAINING PROTEIN 1; MYSM1","url":"https://www.omim.org/entry/612176"},{"mim_id":"610049","title":"SAP DOMAIN-CONTAINING RIBONUCLEOPROTEIN; SARNP","url":"https://www.omim.org/entry/610049"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":5.0},{"tissue":"brain","ntpm":8.9},{"tissue":"lymphoid tissue","ntpm":6.1}],"url":"https://www.proteinatlas.org/search/FLT3"},"hgnc":{"alias_symbol":["STK1","FLK2","CD135"],"prev_symbol":[]},"alphafold":{"accession":"P36888","domains":[{"cath_id":"2.60.40.10","chopping":"33-38_62-162","consensus_level":"high","plddt":75.4143,"start":33,"end":162},{"cath_id":"2.60.40.10","chopping":"164-244","consensus_level":"medium","plddt":79.2042,"start":164,"end":244},{"cath_id":"2.60.40.10","chopping":"246-347","consensus_level":"medium","plddt":88.0927,"start":246,"end":347},{"cath_id":"2.60.40.10","chopping":"350-436","consensus_level":"high","plddt":87.1939,"start":350,"end":436},{"cath_id":"2.60.40.10","chopping":"440-530","consensus_level":"high","plddt":75.6058,"start":440,"end":530},{"cath_id":"1.10.510.10","chopping":"590-700_783-953","consensus_level":"medium","plddt":89.9356,"start":590,"end":953}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P36888","model_url":"https://alphafold.ebi.ac.uk/files/AF-P36888-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P36888-F1-predicted_aligned_error_v6.png","plddt_mean":75.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FLT3","jax_strain_url":"https://www.jax.org/strain/search?query=FLT3"},"sequence":{"accession":"P36888","fasta_url":"https://rest.uniprot.org/uniprotkb/P36888.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P36888/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P36888"}},"corpus_meta":[{"pmid":"12176867","id":"PMC_12176867","title":"The roles of FLT3 in hematopoiesis and leukemia.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12176867","citation_count":1221,"is_preprint":false},{"pmid":"12951584","id":"PMC_12951584","title":"The role of FLT3 in haematopoietic malignancies.","date":"2003","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12951584","citation_count":690,"is_preprint":false},{"pmid":"7621074","id":"PMC_7621074","title":"Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.","date":"1995","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7621074","citation_count":469,"is_preprint":false},{"pmid":"8145851","id":"PMC_8145851","title":"Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8145851","citation_count":401,"is_preprint":false},{"pmid":"12970773","id":"PMC_12970773","title":"FLT3: ITDoes matter in leukemia.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12970773","citation_count":395,"is_preprint":false},{"pmid":"8394751","id":"PMC_8394751","title":"Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8394751","citation_count":311,"is_preprint":false},{"pmid":"8562934","id":"PMC_8562934","title":"Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8562934","citation_count":257,"is_preprint":false},{"pmid":"8618433","id":"PMC_8618433","title":"Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8618433","citation_count":229,"is_preprint":false},{"pmid":"28546144","id":"PMC_28546144","title":"Midostaurin approved for FLT3-mutated AML.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28546144","citation_count":225,"is_preprint":false},{"pmid":"8637232","id":"PMC_8637232","title":"Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8637232","citation_count":203,"is_preprint":false},{"pmid":"21726834","id":"PMC_21726834","title":"All hematopoietic cells develop from hematopoietic stem cells through Flk2/Flt3-positive progenitor cells.","date":"2011","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/21726834","citation_count":193,"is_preprint":false},{"pmid":"19549778","id":"PMC_19549778","title":"Structural and functional alterations of FLT3 in acute myeloid leukemia.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19549778","citation_count":183,"is_preprint":false},{"pmid":"17124058","id":"PMC_17124058","title":"FLT3 mutations: biology and treatment.","date":"2006","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/17124058","citation_count":170,"is_preprint":false},{"pmid":"16873070","id":"PMC_16873070","title":"New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16873070","citation_count":167,"is_preprint":false},{"pmid":"7692230","id":"PMC_7692230","title":"Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7692230","citation_count":166,"is_preprint":false},{"pmid":"12042700","id":"PMC_12042700","title":"Role of FLT3 in leukemia.","date":"2002","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/12042700","citation_count":159,"is_preprint":false},{"pmid":"30514344","id":"PMC_30514344","title":"FLT3 inhibitors in acute myeloid leukemia.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30514344","citation_count":134,"is_preprint":false},{"pmid":"34045454","id":"PMC_34045454","title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.","date":"2021","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/34045454","citation_count":127,"is_preprint":false},{"pmid":"18424665","id":"PMC_18424665","title":"Flk2+ common lymphoid progenitors possess equivalent differentiation potential for the B and T lineages.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18424665","citation_count":122,"is_preprint":false},{"pmid":"32208491","id":"PMC_32208491","title":"Gilteritinib: potent targeting of FLT3 mutations in AML.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32208491","citation_count":116,"is_preprint":false},{"pmid":"9207445","id":"PMC_9207445","title":"Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9207445","citation_count":113,"is_preprint":false},{"pmid":"32581359","id":"PMC_32581359","title":"FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32581359","citation_count":110,"is_preprint":false},{"pmid":"7630197","id":"PMC_7630197","title":"Expression of the flt3 receptor and its ligand on hematopoietic cells.","date":"1995","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/7630197","citation_count":109,"is_preprint":false},{"pmid":"7643626","id":"PMC_7643626","title":"Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.","date":"1995","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/7643626","citation_count":107,"is_preprint":false},{"pmid":"7681159","id":"PMC_7681159","title":"Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7681159","citation_count":102,"is_preprint":false},{"pmid":"8590775","id":"PMC_8590775","title":"Biology of flt3 ligand and receptor.","date":"1995","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/8590775","citation_count":100,"is_preprint":false},{"pmid":"8384358","id":"PMC_8384358","title":"Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8384358","citation_count":96,"is_preprint":false},{"pmid":"22797419","id":"PMC_22797419","title":"FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22797419","citation_count":95,"is_preprint":false},{"pmid":"19467916","id":"PMC_19467916","title":"FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.","date":"2009","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/19467916","citation_count":94,"is_preprint":false},{"pmid":"28538663","id":"PMC_28538663","title":"The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28538663","citation_count":91,"is_preprint":false},{"pmid":"34024909","id":"PMC_34024909","title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34024909","citation_count":91,"is_preprint":false},{"pmid":"28470536","id":"PMC_28470536","title":"FLT3-ITD and its current role in acute myeloid leukaemia.","date":"2017","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28470536","citation_count":85,"is_preprint":false},{"pmid":"9720755","id":"PMC_9720755","title":"FLT3: receptor and ligand. Biology and potential clinical application.","date":"1998","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/9720755","citation_count":79,"is_preprint":false},{"pmid":"31217189","id":"PMC_31217189","title":"PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31217189","citation_count":78,"is_preprint":false},{"pmid":"8634436","id":"PMC_8634436","title":"The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8634436","citation_count":77,"is_preprint":false},{"pmid":"16146838","id":"PMC_16146838","title":"Signal transduction of oncogenic Flt3.","date":"2005","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16146838","citation_count":76,"is_preprint":false},{"pmid":"8543798","id":"PMC_8543798","title":"flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8543798","citation_count":73,"is_preprint":false},{"pmid":"18760705","id":"PMC_18760705","title":"Targeting FLT3 for the treatment of leukemia.","date":"2008","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18760705","citation_count":70,"is_preprint":false},{"pmid":"16146839","id":"PMC_16146839","title":"FLT3 tyrosine kinase inhibitors.","date":"2005","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16146839","citation_count":68,"is_preprint":false},{"pmid":"27872057","id":"PMC_27872057","title":"How I treat FLT3-mutated AML.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27872057","citation_count":65,"is_preprint":false},{"pmid":"25231999","id":"PMC_25231999","title":"Targeting FLT3 to treat leukemia.","date":"2014","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/25231999","citation_count":64,"is_preprint":false},{"pmid":"31528345","id":"PMC_31528345","title":"Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.","date":"2019","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/31528345","citation_count":64,"is_preprint":false},{"pmid":"32703795","id":"PMC_32703795","title":"Potential targeting of FLT3 acute myeloid leukemia.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/32703795","citation_count":63,"is_preprint":false},{"pmid":"16146837","id":"PMC_16146837","title":"Clinical significance of FLT3 in leukemia.","date":"2005","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16146837","citation_count":59,"is_preprint":false},{"pmid":"15253381","id":"PMC_15253381","title":"FLT3: receptor and ligand.","date":"2004","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/15253381","citation_count":57,"is_preprint":false},{"pmid":"15180525","id":"PMC_15180525","title":"Flt3 receptor tyrosine kinase as a drug target in leukemia.","date":"2004","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15180525","citation_count":57,"is_preprint":false},{"pmid":"17655729","id":"PMC_17655729","title":"FLT3 inhibition in acute myeloid leukaemia.","date":"2007","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/17655729","citation_count":56,"is_preprint":false},{"pmid":"15352981","id":"PMC_15352981","title":"FLT3 mutations in myeloid sarcoma.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/15352981","citation_count":54,"is_preprint":false},{"pmid":"15583855","id":"PMC_15583855","title":"Normal and oncogenic FLT3.","date":"2004","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/15583855","citation_count":51,"is_preprint":false},{"pmid":"27775694","id":"PMC_27775694","title":"Inhibition of FLT3 in AML: a focus on sorafenib.","date":"2016","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/27775694","citation_count":51,"is_preprint":false},{"pmid":"25295230","id":"PMC_25295230","title":"The Biology and Targeting of FLT3 in Pediatric Leukemia.","date":"2014","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25295230","citation_count":51,"is_preprint":false},{"pmid":"19162530","id":"PMC_19162530","title":"Mechanisms of resistance to FLT3 inhibitors.","date":"2009","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/19162530","citation_count":51,"is_preprint":false},{"pmid":"24333663","id":"PMC_24333663","title":"Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non-self-renewing multipotent hematopoietic progenitor cells.","date":"2013","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24333663","citation_count":50,"is_preprint":false},{"pmid":"23687091","id":"PMC_23687091","title":"FLT3 inhibitor-induced neutrophilic dermatosis.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23687091","citation_count":50,"is_preprint":false},{"pmid":"34111291","id":"PMC_34111291","title":"Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34111291","citation_count":49,"is_preprint":false},{"pmid":"12400596","id":"PMC_12400596","title":"FLT3 in human hematologic malignancies.","date":"2002","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/12400596","citation_count":49,"is_preprint":false},{"pmid":"37696819","id":"PMC_37696819","title":"Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.","date":"2023","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/37696819","citation_count":49,"is_preprint":false},{"pmid":"37892567","id":"PMC_37892567","title":"A Review of FLT3 Kinase Inhibitors in AML.","date":"2023","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37892567","citation_count":48,"is_preprint":false},{"pmid":"25797966","id":"PMC_25797966","title":"FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION.","date":"2015","source":"Nagoya journal of medical science","url":"https://pubmed.ncbi.nlm.nih.gov/25797966","citation_count":47,"is_preprint":false},{"pmid":"34097779","id":"PMC_34097779","title":"Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy.","date":"2021","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34097779","citation_count":46,"is_preprint":false},{"pmid":"19684517","id":"PMC_19684517","title":"FLT3 inhibition as a targeted therapy for acute myeloid leukemia.","date":"2009","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19684517","citation_count":45,"is_preprint":false},{"pmid":"10671293","id":"PMC_10671293","title":"Flt3 ligand (FL) and its influence on immune reactivity.","date":"2000","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/10671293","citation_count":45,"is_preprint":false},{"pmid":"21245757","id":"PMC_21245757","title":"FLT3 inhibitors: a story of the old and the new.","date":"2011","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21245757","citation_count":44,"is_preprint":false},{"pmid":"29257272","id":"PMC_29257272","title":"High expression of FLT3 is a risk factor in leukemia.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29257272","citation_count":42,"is_preprint":false},{"pmid":"27450971","id":"PMC_27450971","title":"FLT3 Inhibitors for Treating Acute Myeloid Leukemia.","date":"2016","source":"Clinical lymphoma, myeloma & leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27450971","citation_count":41,"is_preprint":false},{"pmid":"36652946","id":"PMC_36652946","title":"Flt3- and Tie2-Cre tracing identifies regeneration in sepsis from multipotent progenitors but not hematopoietic stem cells.","date":"2023","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/36652946","citation_count":41,"is_preprint":false},{"pmid":"35267471","id":"PMC_35267471","title":"Role of Biomarkers in FLT3 AML.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35267471","citation_count":37,"is_preprint":false},{"pmid":"28421420","id":"PMC_28421420","title":"The Future of Targeting FLT3 Activation in AML.","date":"2017","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/28421420","citation_count":37,"is_preprint":false},{"pmid":"22895180","id":"PMC_22895180","title":"Mapping differentiation pathways from hematopoietic stem cells using Flk2/Flt3 lineage tracing.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22895180","citation_count":37,"is_preprint":false},{"pmid":"28213513","id":"PMC_28213513","title":"RUNX1 cooperates with FLT3-ITD to induce leukemia.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28213513","citation_count":37,"is_preprint":false},{"pmid":"7519507","id":"PMC_7519507","title":"The expression of FMS, KIT and FLT3 in hematopoietic malignancies.","date":"1994","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/7519507","citation_count":36,"is_preprint":false},{"pmid":"9664159","id":"PMC_9664159","title":"Biologic effects and potential clinical applications of Flt3 ligand.","date":"1998","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9664159","citation_count":36,"is_preprint":false},{"pmid":"28223820","id":"PMC_28223820","title":"FLT3 inhibitors: clinical potential in acute myeloid leukemia.","date":"2017","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28223820","citation_count":35,"is_preprint":false},{"pmid":"31808872","id":"PMC_31808872","title":"The growing landscape of FLT3 inhibition in AML.","date":"2019","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/31808872","citation_count":35,"is_preprint":false},{"pmid":"23340802","id":"PMC_23340802","title":"C/EBPα and MYB regulate FLT3 expression in AML.","date":"2013","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/23340802","citation_count":34,"is_preprint":false},{"pmid":"24314260","id":"PMC_24314260","title":"FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis.","date":"2013","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24314260","citation_count":33,"is_preprint":false},{"pmid":"24682858","id":"PMC_24682858","title":"FLT3 inhibitors in AML: are we there yet?","date":"2014","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/24682858","citation_count":32,"is_preprint":false},{"pmid":"11587362","id":"PMC_11587362","title":"FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.","date":"2001","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11587362","citation_count":32,"is_preprint":false},{"pmid":"8943846","id":"PMC_8943846","title":"Soluble thrombopoietin receptor (Mpl) and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for Flt3/Flk2.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8943846","citation_count":32,"is_preprint":false},{"pmid":"38917943","id":"PMC_38917943","title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.","date":"2024","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/38917943","citation_count":32,"is_preprint":false},{"pmid":"8702727","id":"PMC_8702727","title":"Phosphatidylinositol-3' kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702727","citation_count":31,"is_preprint":false},{"pmid":"29316714","id":"PMC_29316714","title":"Targeting FLT3 Mutations in Acute Myeloid Leukemia.","date":"2018","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/29316714","citation_count":31,"is_preprint":false},{"pmid":"33990705","id":"PMC_33990705","title":"Myeloid/lymphoid neoplasms with FLT3 rearrangement.","date":"2021","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/33990705","citation_count":30,"is_preprint":false},{"pmid":"30410361","id":"PMC_30410361","title":"Clinical use of FLT3 inhibitors in acute myeloid leukemia.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30410361","citation_count":30,"is_preprint":false},{"pmid":"16263569","id":"PMC_16263569","title":"Mutant FLT3 signaling contributes to a block in myeloid differentiation.","date":"2005","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/16263569","citation_count":29,"is_preprint":false},{"pmid":"29209600","id":"PMC_29209600","title":"Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.","date":"2017","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/29209600","citation_count":28,"is_preprint":false},{"pmid":"35884458","id":"PMC_35884458","title":"\"FLipping\" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35884458","citation_count":27,"is_preprint":false},{"pmid":"31955503","id":"PMC_31955503","title":"CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31955503","citation_count":27,"is_preprint":false},{"pmid":"14640939","id":"PMC_14640939","title":"Novel FLT3 tyrosine kinase inhibitors.","date":"2003","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/14640939","citation_count":26,"is_preprint":false},{"pmid":"27323399","id":"PMC_27323399","title":"An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27323399","citation_count":26,"is_preprint":false},{"pmid":"36226489","id":"PMC_36226489","title":"Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.","date":"2023","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/36226489","citation_count":25,"is_preprint":false},{"pmid":"37246158","id":"PMC_37246158","title":"Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.","date":"2023","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/37246158","citation_count":23,"is_preprint":false},{"pmid":"8843540","id":"PMC_8843540","title":"Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis.","date":"1996","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/8843540","citation_count":23,"is_preprint":false},{"pmid":"30552988","id":"PMC_30552988","title":"The role of SRC family kinases in FLT3 signaling.","date":"2018","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30552988","citation_count":23,"is_preprint":false},{"pmid":"24468836","id":"PMC_24468836","title":"Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?","date":"2014","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24468836","citation_count":23,"is_preprint":false},{"pmid":"27748370","id":"PMC_27748370","title":"DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27748370","citation_count":23,"is_preprint":false},{"pmid":"35532877","id":"PMC_35532877","title":"FLT3-targeted treatment for acute myeloid leukemia.","date":"2022","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35532877","citation_count":22,"is_preprint":false},{"pmid":"39538314","id":"PMC_39538314","title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.","date":"2024","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39538314","citation_count":21,"is_preprint":false},{"pmid":"28522571","id":"PMC_28522571","title":"FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/28522571","citation_count":21,"is_preprint":false},{"pmid":"33811956","id":"PMC_33811956","title":"Strategies targeting FLT3 beyond the kinase inhibitors.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33811956","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44868,"output_tokens":6222,"usd":0.113967,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14893,"output_tokens":6324,"usd":0.116282,"stage2_stop_reason":"end_turn"},"total_usd":0.230249,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"FLT3/FLK2 receptor tyrosine kinase has intrinsic tyrosine kinase activity; a point mutation in the conserved phosphoryltransferase domain inactivates catalytic function; a chimeric CSF-1R extracellular domain/FLT3 kinase domain construct demonstrated transforming activity (anchorage-independent growth) upon CSF-1 stimulation, establishing ligand-induced kinase activation as the mechanism of transformation.\",\n      \"method\": \"Site-directed mutagenesis of kinase domain, chimeric receptor construct expressed in COS-1 cells, anchorage-independent growth assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with active-site mutagenesis and chimeric receptor reconstitution, single lab with two orthogonal functional methods\",\n      \"pmids\": [\"8384358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"FLT3 protein undergoes N-linked glycosylation maturation: a 143 kDa high-mannose form is processed to a 158 kDa complex-carbohydrate form that is expressed on the cell surface. FLT3 is heavily phosphorylated on tyrosine even in the absence of ligand, resembling c-ErbB2.\",\n      \"method\": \"Immunoprecipitation with polyclonal antibodies, pulse-chase analysis in COS-7 transfectants, N-glycosidase F digestion, cell-surface labeling\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical reconstitution with multiple orthogonal methods (pulse-chase, glycosidase digestion, surface labeling) in a single rigorous study\",\n      \"pmids\": [\"7681159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Activated FLT3/FLK2 kinase recruits and/or phosphorylates phospholipase C-γ1, Ras-GAP, PI3K p85 subunit, Shc, Grb2, Vav, Fyn, and Src. Physical association with the FLT3 cytoplasmic domain was demonstrated for PLC-γ1, PI3K p85, Shc, Grb2, and Src family kinases, but not for Ras-GAP, Vav, or Nck. Cell-type-specific differences in tyrosine phosphorylation of p85 and Shc were observed.\",\n      \"method\": \"Chimeric CSF-1R/FLK2 receptor in NIH 3T3 and Ba/F3 cells, co-immunoprecipitation, tyrosine phosphorylation assays, factor-independence assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstituted chimeric receptor system with reciprocal co-IP and functional readouts (mitogenesis, IL-3 independence), multiple substrates tested\",\n      \"pmids\": [\"7692230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"FLT3 ligand (FL) was purified to homogeneity from mouse thymic stromal cells, partially sequenced, and shown to be encoded by multiple cDNA variants; some contain transmembrane segments indicating a membrane-bound precursor requiring proteolytic processing to release soluble ligand. FL synergizes with IL-3, IL-6, and GM-CSF to stimulate mouse stem cells and a primitive human progenitor population.\",\n      \"method\": \"Protein purification, partial sequencing, cDNA cloning, functional proliferation assays with purified ligand\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ligand purified to homogeneity, sequenced, cDNAs cloned, and functional activity confirmed; foundational biochemical characterization\",\n      \"pmids\": [\"8145851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Mice with targeted disruption of flk2/flt3 are viable and healthy but have specific deficiencies in primitive B lymphoid progenitors. Bone marrow transplantation revealed further deficiency in T cell and myeloid reconstitution by mutant stem cells. Double knockout of c-kit and flk2 produced severe reductions in hematopoietic cell numbers and postnatal lethality, establishing genetic epistasis between FLT3 and c-KIT in multipotent progenitor maintenance.\",\n      \"method\": \"Gene targeting (knockout mice), bone marrow transplantation, flow cytometric analysis of hematopoietic populations\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function knockout with defined cellular phenotype; genetic epistasis established via double-knockout; replicated across multiple assays\",\n      \"pmids\": [\"7621074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Monoclonal antibodies against the FLT3 extracellular domain can mimic FL activity, activating and modulating the receptor, establishing that the extracellular domain is sufficient for receptor activation. FLT3 surface expression is restricted to CD34+ hematopoietic progenitors and leukemic blasts; most CD34+FLT3+ cells co-express CD117 (KIT).\",\n      \"method\": \"Monoclonal antibody generation, functional receptor activation assays, flow cytometry (3-color analysis)\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional agonist antibody assay plus direct surface phenotyping; single lab, two orthogonal approaches\",\n      \"pmids\": [\"8637232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Stimulation of leukemic patient samples with FLT3 ligand results in autophosphorylation of the FLT3 receptor, confirming that overexpressed FLT3 in AML cells is functional and capable of ligand-induced kinase activation.\",\n      \"method\": \"Western blotting with anti-FLT3 antisera, FLT3 ligand stimulation and autophosphorylation assay in primary leukemic bone marrow samples\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct autophosphorylation assay on primary patient samples; single lab, functional readout\",\n      \"pmids\": [\"8562934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PI3K binds to a unique site in the carboxy tail of murine FLT3/FLK2; however, mutant receptors unable to couple to PI3K retain full mitogenic signaling and normal receptor down-regulation in NIH 3T3 fibroblasts and Ba/F3 cells, demonstrating that PI3K is not required for FLT3-mediated mitogenesis or receptor internalization.\",\n      \"method\": \"Mutagenesis of PI3K binding site, transfection into NIH 3T3 and Ba/F3 cells, proliferation assays, receptor down-regulation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis with functional reconstitution in two cell types; single lab, multiple orthogonal methods; rigorous negative result\",\n      \"pmids\": [\"8702727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FLT3 internal tandem duplication (ITD) mutations in the juxtamembrane domain result in constitutive, ligand-independent tyrosine kinase activation. FLT3-ITD confers factor-independent growth to Ba/F3 and 32D cells, activates STAT, RAS/MAPK, and PI3K/AKT pathways, and causes a myeloproliferative disorder upon retroviral transduction into primary murine bone marrow. Mutations that abrogate kinase activity abolish transforming properties.\",\n      \"method\": \"Retroviral transduction into Ba/F3 and 32D cells, factor-independence assay, signaling pathway analysis, murine bone marrow transduction/transplantation model, kinase-dead mutagenesis\",\n      \"journal\": \"Current opinion in hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (cell transformation, in vivo mouse model, kinase-dead mutant) reported across multiple labs\",\n      \"pmids\": [\"12042700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Oncogenic FLT3 mutations (ITD and TKD point mutations) result in constitutive activation of downstream pathways shared with wild-type FLT3 (PI3K, Src kinases, MAPK) but additionally cause aberrant strong activation of STAT5 and induction of STAT5 target genes, as well as repression of myeloid transcription factors C/EBPβ and PU.1, which are not activated by wild-type receptor.\",\n      \"method\": \"Signal transduction analysis in cell lines expressing wild-type vs. mutant FLT3, immunoprecipitation, reporter assays, gene expression analysis\",\n      \"journal\": \"International journal of hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-line-based signaling comparison; single review synthesizing experimental data from multiple labs\",\n      \"pmids\": [\"16146838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Lineage tracing using a Flk2-Cre mouse model demonstrated that all mature hematopoietic lineages—including megakaryocyte/erythroid cells—pass through a Flk2-expressing non-self-renewing progenitor stage during steady-state hematopoiesis, after irradiation stress, and upon HSC transplantation. HSC origin and maintenance do not include a Flk2+ stage, dissociating HSC self-renewal from Flk2 expression.\",\n      \"method\": \"In vivo lineage tracing (Flk2-Cre × Rosa26-reporter mice), flow cytometry of all hematopoietic lineages, bone marrow transplantation\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic fate mapping with multiple conditions tested (steady-state, stress, transplant) provides definitive pathway position; replicated across experimental contexts\",\n      \"pmids\": [\"21726834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Flk2/FLT3 is critical for proliferative expansion of multipotent progenitors common to all lymphoid and myeloid lineages; Flk2 deficiency impairs generation of both lymphoid and myeloid progenitors by abrogating propagation of their common upstream precursor without affecting lineage choice. FLT3-ITD failed to transform primary hematopoietic progenitors from Cdk6-/- mice, and FLT3-ITD signaling upregulates CDK6 through the SRC-family kinase HCK, establishing an FLT3/HCK/CDK6 pathway.\",\n      \"method\": \"Flk2 knockout mice, transplantation of purified progenitors, lineage analysis; separate pathway study using Cdk6-/- mice and HCK inhibition in FLT3-ITD AML cells\",\n      \"journal\": \"Experimental hematology; Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout combined with progenitor transplantation; epistasis established by Cdk6-/- rescue experiment; two separate papers\",\n      \"pmids\": [\"24333663\", \"27323399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FLT3 and FLT3-ITD directly bind and phosphorylate the CDK inhibitor p27Kip1 at tyrosine residue 88, inactivating its cell-cycle inhibitory function. Inhibition of FLT3-ITD kinase reduced p27-Y88 phosphorylation and caused cell cycle arrest. Phospho-Y88-p27 was detected in primary AML patient samples.\",\n      \"method\": \"Co-immunoprecipitation of FLT3 and p27, in vitro phosphorylation assay, FLT3 inhibitor (AC220) treatment in cell lines and primary AML patient samples, flow cytometry for cell cycle\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct in vitro kinase assay demonstrating substrate phosphorylation, confirmed by co-IP and validated in primary patient samples; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28522571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT1 methylates FLT3-ITD protein at arginine residues 972/973, promoting AML maintenance. This methylation occurs independently of FLT3 kinase activity and persists following FLT3 kinase inhibition. FLT3-ITD methylation cross-talks with phosphorylation at tyrosine 969. Genetic or pharmacological PRMT1 inhibition blocked FLT3-ITD+ AML cell maintenance.\",\n      \"method\": \"Co-immunoprecipitation, genome-wide analysis, PRMT1 knockout mouse studies, mass spectrometry, site-directed mutagenesis, patient-derived xenograft models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — identification of PTM writer (PRMT1), specific methylation sites by MS, functional validation with mutagenesis and in vivo xenograft model; multiple orthogonal methods\",\n      \"pmids\": [\"31217189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FLT3-ITD is S-palmitoylated by the palmitoyl acyltransferase ZDHHC6, which retains FLT3-ITD in the endoplasmic reticulum and restricts signaling to constitutive STAT5 phosphorylation. Disruption of palmitoylation redirects FLT3-ITD to the plasma membrane, rewiring downstream signaling to additionally activate AKT and ERK pathways, and exacerbates leukemia progression in xenotransplant models.\",\n      \"method\": \"Palmitoylation assay, ZDHHC6 knockdown/overexpression, subcellular fractionation, signaling analysis, xenotransplant mouse models, primary AML patient samples\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — identification of palmitoylation writer (ZDHHC6), functional consequence on subcellular localization and signaling rewiring, validated in vivo and in primary patient samples\",\n      \"pmids\": [\"34111291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FLT3 TKI (gilteritinib/sorafenib) treatment dissociates BIM from MCL-1 but increases BIM-BCL-2 binding. Combined FLT3 TKI + venetoclax (BCL-2 inhibitor) treatment dissociates BIM from both BCL-2 and MCL-1 and increases BIM-BAX binding, driving apoptosis. This mechanistic cross-talk establishes a pro-survival role of BCL-2 as a BIM reservoir following FLT3 inhibition.\",\n      \"method\": \"Co-immunoprecipitation of BIM with BCL-2/MCL-1/BAX, proliferation assays, apoptosis assays in FLT3-ITD cell lines and primary AML samples\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP of multiple BCL-2 family members, functional apoptosis readouts in cell lines and primary samples; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"34024909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DOCK2, a guanine nucleotide exchange factor for Rho GTPases, co-immunoprecipitates with both wild-type FLT3 and FLT3-ITD in leukemia cells. DOCK2 knockdown selectively reduces proliferation and colony formation in FLT3-overactive leukemia cells and sensitizes them to cytarabine and FLT3 inhibitors; prolonged survival in a mouse xenograft model was observed.\",\n      \"method\": \"Mass spectrometry-based protein interaction screen, co-immunoprecipitation, shRNA knockdown, proliferation/colony assays, mouse xenograft model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-identified interaction confirmed by co-IP; functional validation by KD with in vitro and in vivo phenotypes; single lab\",\n      \"pmids\": [\"27748370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The transcription factors MYB and C/EBPα directly regulate FLT3 expression: MYB binds the FLT3 promoter and C/EBPα binds an intronic regulatory module, as demonstrated by chromatin accessibility assays and epigenetic markings in murine AML cells and primary human AML patient samples.\",\n      \"method\": \"Chromatin accessibility assays, chromatin immunoprecipitation (ChIP), epigenetic histone mark analysis, gene expression profiling in AML patient samples\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating in vivo binding of MYB and C/EBPα to FLT3 regulatory elements; validated in primary human AML; single lab\",\n      \"pmids\": [\"23340802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FLT3-ITD directly impacts RUNX1 activity by upregulating and phosphorylating RUNX1, which then cooperates with FLT3-ITD to induce AML. Inactivating RUNX1 in FLT3-ITD tumors releases differentiation block and downregulates ribosome biogenesis genes. HHEX was identified as a direct RUNX1 and FLT3-ITD target gene that can substitute for RUNX1 in cooperating with FLT3-ITD.\",\n      \"method\": \"Genetic co-expression experiments in primary hematopoietic progenitors, RUNX1 inactivation, gene expression analysis, ChIP, murine AML model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by RUNX1 inactivation in FLT3-ITD tumors with defined phenotypic readouts; ChIP identifies direct target; in vivo model; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28213513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ligand-induced FLT3 dimerization and autophosphorylation creates binding sites for SRC family kinases (SFKs), which are recruited to specific phosphotyrosine residues on FLT3. SFKs regulate downstream RAS/ERK signaling through GAB2 and SHC adaptor proteins, and negatively regulate FLT3 signaling through phosphorylation of the ubiquitin E3 ligase CBL. Individual SFK members have distinct positive vs. negative signaling roles downstream of FLT3.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, SFK knockdown/inhibition studies, signaling pathway analysis\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — review synthesizing experimental co-IP and functional data from multiple studies; mechanistic roles of individual SFKs established across labs\",\n      \"pmids\": [\"30552988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A low-frequency intronic FLT3 variant (rs76428106-C) generates a cryptic splice site introducing a stop codon in 30% of transcripts, predicted to encode a truncated protein lacking tyrosine kinase domains (loss-of-function). Each copy of this variant doubles plasma FLT3 ligand levels, demonstrating a compensatory feedback mechanism where reduced FLT3 receptor function elevates ligand.\",\n      \"method\": \"RNA sequencing to identify cryptic splice site, GWAS, plasma FLT3 ligand quantification by ELISA\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — RNA sequencing directly demonstrates aberrant splicing; ELISA quantifies compensatory ligand elevation; large-scale human genetics study with functional validation\",\n      \"pmids\": [\"32581359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FLT3-ITD mutations activate tyrosine kinase through receptor dimerization in a FLT3 ligand-independent manner, contributing to a block in myeloid differentiation in addition to proliferative and anti-apoptotic signaling. FLT3 tyrosine kinase inhibitors suppress growth and induce apoptosis and differentiation of FLT3-ITD-expressing leukemia cells.\",\n      \"method\": \"Cell line studies with FLT3-ITD expression, differentiation assays, apoptosis assays, TKI treatment experiments\",\n      \"journal\": \"Leukemia & lymphoma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell-line data demonstrating differentiation block and its reversal by kinase inhibition; mechanism of ITD-induced dimerization established\",\n      \"pmids\": [\"16263569\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FLT3 is a class III receptor tyrosine kinase expressed on primitive hematopoietic progenitors that, upon binding its transmembrane/soluble ligand FL, dimerizes and autophosphorylates, recruiting signal transducers including PLC-γ1, PI3K p85, Shc, Grb2, and SRC family kinases (which in turn regulate RAS/ERK via GAB2/SHC and negatively regulate FLT3 via CBL), while activating STAT, RAS/MAPK, and PI3K/AKT pathways to drive proliferation, survival, and differentiation of hematopoietic progenitors through a obligate Flk2+ intermediate stage; oncogenic FLT3-ITD mutations cause ligand-independent kinase activation through juxtamembrane dimerization, aberrantly strong STAT5 activation, repression of myeloid transcription factors, and phosphorylation/inactivation of the CDK inhibitor p27Kip1, while its subcellular localization and signaling are controlled post-translationally by ZDHHC6-mediated S-palmitoylation (retaining ITD in the ER for STAT5 signaling) and PRMT1-mediated arginine methylation at R972/973 (independently of kinase activity).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FLT3 (FLK2) is a class III receptor tyrosine kinase expressed on CD34+ hematopoietic progenitors and leukemic blasts that drives proliferative expansion and survival of multipotent and lineage-restricted progenitors [#0, #5, #13]. Its ligand FL, produced as a membrane-bound precursor that is proteolytically processed to a soluble form, synergizes with IL-3, IL-6, and GM-CSF to stimulate stem and primitive progenitor populations [#3]; ligand engagement of the extracellular domain induces receptor dimerization and autophosphorylation, and agonist antibodies against the ectodomain are sufficient to mimic this activation [#0, #5]. The mature, complex-glycosylated receptor recruits and phosphorylates PLC-\\u03b31, PI3K p85, Shc, Grb2, and SRC-family kinases at specific phosphotyrosine sites, with SFKs routing RAS/ERK signaling through GAB2/SHC and providing negative feedback via the E3 ligase CBL, while PI3K coupling is dispensable for mitogenesis and receptor internalization [#1, #2, #7, #19]. During development FLT3 is genetically required for propagation of a common lymphoid/myeloid progenitor and acts in epistasis with c-KIT in multipotent progenitor maintenance; fate mapping places a non-self-renewing Flk2+ stage on the path to all mature lineages while excluding it from HSC self-renewal [#4, #10, #13]. Internal tandem duplication (ITD) mutations in the juxtamembrane domain cause ligand-independent, dimerization-driven constitutive kinase activation that confers factor-independent growth and a myeloproliferative disorder, signaling through PI3K/AKT, RAS/MAPK and aberrantly strong STAT5 while repressing myeloid transcription factors C/EBP\\u03b2 and PU.1 to block differentiation [#8, #9, #21]. Oncogenic FLT3 additionally phosphorylates the CDK inhibitor p27Kip1 at Y88 to neutralize cell-cycle inhibition, drives an HCK/CDK6 proliferative axis, and cooperates with phosphorylated RUNX1 (and its target HHEX) to enforce the differentiation block [#12, #13, #18]. FLT3-ITD localization and signaling are tuned post-translationally: ZDHHC6-mediated S-palmitoylation retains the receptor in the ER and restricts output to constitutive STAT5, whereas loss of palmitoylation redirects it to the plasma membrane and rewires signaling to AKT/ERK, and PRMT1-mediated arginine methylation at R972/973 supports AML maintenance independently of kinase activity [#13, #14]. FLT3 expression is set by MYB binding its promoter and C/EBP\\u03b1 binding an intronic module [#17].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that FLT3 is a functional tyrosine kinase whose ligand-induced catalytic activation is the basis of cellular transformation, defining the receptor's core enzymatic mechanism.\",\n      \"evidence\": \"Active-site mutagenesis and a CSF-1R/FLT3 chimeric receptor scored by anchorage-independent growth in COS-1 cells\",\n      \"pmids\": [\"8384358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native ligand not yet identified\", \"Downstream effectors undefined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defined FLT3 as a glycosylated cell-surface receptor maturing from a high-mannose to a complex-carbohydrate form, linking glycan processing to surface display.\",\n      \"evidence\": \"Pulse-chase, N-glycosidase F digestion and cell-surface labeling of COS-7 transfectants\",\n      \"pmids\": [\"7681159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of ligand-independent tyrosine phosphorylation unclear\", \"No structural model of the receptor\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identified the proximal signal transducers physically recruited to the activated receptor, mapping the immediate signaling complex.\",\n      \"evidence\": \"Chimeric CSF-1R/FLK2 receptor with reciprocal co-IP and mitogenesis/IL-3-independence readouts in NIH 3T3 and Ba/F3 cells\",\n      \"pmids\": [\"7692230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each effector to proliferation not resolved\", \"Cell-type differences in p85/Shc phosphorylation unexplained\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Purified and cloned the FLT3 ligand, establishing that a membrane-bound precursor is processed to a soluble cytokine that synergizes with other factors on stem/progenitor cells.\",\n      \"evidence\": \"Protein purification to homogeneity, partial sequencing, cDNA cloning and proliferation assays from mouse thymic stroma\",\n      \"pmids\": [\"8145851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease responsible for shedding not identified\", \"Stoichiometry of ligand-receptor dimerization not defined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Assigned FLT3 a physiological role in hematopoiesis and placed it genetically alongside c-KIT, distinguishing in vivo function from cell-line biochemistry.\",\n      \"evidence\": \"Flk2/flt3 knockout and flk2/c-kit double-knockout mice with bone marrow transplantation and lineage flow cytometry\",\n      \"pmids\": [\"7621074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of B-lineage selectivity unclear\", \"Mechanism of KIT epistasis not defined at the signaling level\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed the extracellular domain alone is sufficient for activation and mapped FLT3 surface expression to CD34+ progenitors and leukemic blasts, tying the receptor to leukemia-relevant cells.\",\n      \"evidence\": \"Agonist monoclonal antibodies and 3-color flow cytometry\",\n      \"pmids\": [\"8637232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab antibody mimicry\", \"Quantitative comparison to native ligand activation lacking\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated that FLT3 overexpressed on primary AML blasts is functional and ligand-responsive, validating the receptor as active in patient disease.\",\n      \"evidence\": \"FL stimulation and anti-FLT3 immunoblot autophosphorylation assays on primary leukemic marrow\",\n      \"pmids\": [\"8562934\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish causal role in leukemogenesis\", \"Downstream consequences in blasts not measured\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Used loss-of-coupling mutagenesis to show PI3K is dispensable for FLT3 mitogenesis and internalization, refining which effectors are essential versus auxiliary.\",\n      \"evidence\": \"PI3K-binding-site mutants in NIH 3T3 and Ba/F3 cells with proliferation and down-regulation assays\",\n      \"pmids\": [\"8702727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PI3K function in other cell contexts not excluded\", \"Compensating effectors not identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the oncogenic ITD mechanism: juxtamembrane duplications cause ligand-independent constitutive kinase activation that transforms cells and causes myeloproliferative disease in vivo, linking a specific mutation to leukemia.\",\n      \"evidence\": \"Retroviral ITD transduction of Ba/F3, 32D and primary murine marrow with factor-independence, signaling analysis, transplantation and kinase-dead controls\",\n      \"pmids\": [\"12042700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative difference in signaling vs wild-type not yet detailed\", \"Mechanism of ligand-independent dimerization not structurally defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Distinguished oncogenic from physiological signaling by showing mutant FLT3 aberrantly activates STAT5 and represses myeloid transcription factors, and that ITD-driven dimerization blocks differentiation reversibly by TKI.\",\n      \"evidence\": \"Comparative signaling, reporter and gene-expression analysis in wild-type vs mutant FLT3 cell lines; differentiation/apoptosis assays under TKI\",\n      \"pmids\": [\"16146838\", \"16263569\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT5 target genes in primary cells incompletely mapped\", \"Mechanism of C/EBP\\u03b2/PU.1 repression not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved FLT3's exact position in the hematopoietic hierarchy, showing all mature lineages transit a Flk2+ non-self-renewing stage that is excluded from HSC self-renewal.\",\n      \"evidence\": \"Flk2-Cre x Rosa26 in vivo lineage tracing across steady-state, stress and transplant conditions\",\n      \"pmids\": [\"21726834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address whether FLT3 signaling instructs lineage transitions\", \"Megakaryocyte/erythroid routing details limited\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established FLT3 as required for proliferative expansion of a common multipotent progenitor and identified an FLT3/HCK/CDK6 axis required for ITD transformation, connecting the receptor to cell-cycle machinery.\",\n      \"evidence\": \"Flk2 knockout with purified-progenitor transplantation; Cdk6-/- rescue and HCK inhibition in FLT3-ITD AML cells\",\n      \"pmids\": [\"24333663\", \"27323399\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How HCK selectively upregulates CDK6 not mechanistically detailed\", \"Two separate studies not jointly validated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the transcriptional control of FLT3 itself, identifying MYB and C/EBP\\u03b1 as direct regulators binding promoter and intronic elements.\",\n      \"evidence\": \"Chromatin accessibility, ChIP and histone-mark analysis in murine AML and primary human AML\",\n      \"pmids\": [\"23340802\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Functional impact of each element on FLT3 dosage not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified p27Kip1-Y88 as a direct FLT3 substrate, providing a kinase-to-cell-cycle link by which the receptor inactivates a CDK inhibitor.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay and AC220 treatment in cell lines and primary AML samples\",\n      \"pmids\": [\"28522571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution relative to STAT5/CDK6 routes not quantified\", \"Structural basis of p27 recognition unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed FLT3-ITD cooperates with phosphorylated RUNX1 (and its target HHEX) to enforce differentiation block and ribosome biogenesis, defining a transcriptional cooperator of the oncogene.\",\n      \"evidence\": \"Co-expression, RUNX1 inactivation, ChIP and gene-expression analysis in a murine AML model\",\n      \"pmids\": [\"28213513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical RUNX1 phosphorylation by FLT3 not isolated\", \"Generality across AML subtypes untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Detailed the SRC-family kinase node downstream of FLT3, showing SFKs route RAS/ERK via GAB2/SHC while negatively feeding back through CBL, with member-specific roles.\",\n      \"evidence\": \"Co-IP, phosphorylation and SFK knockdown/inhibition studies synthesized in a review\",\n      \"pmids\": [\"30552988\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Individual SFK assignments rest on aggregated data\", \"In vivo relevance of CBL feedback in AML not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established arginine methylation as a kinase-independent regulatory layer, identifying PRMT1 as the writer at R972/973 required for FLT3-ITD AML maintenance.\",\n      \"evidence\": \"Co-IP, mass spectrometry, site-directed mutagenesis, PRMT1 knockout and PDX models\",\n      \"pmids\": [\"31217189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reader of the methyl mark not identified\", \"Mechanism of cross-talk with Y969 phosphorylation incompletely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a population-level feedback loop in which a loss-of-function FLT3 splice variant doubles plasma FL, showing receptor function reciprocally sets ligand levels in humans.\",\n      \"evidence\": \"RNA-seq identification of a cryptic splice site, GWAS and plasma FL ELISA\",\n      \"pmids\": [\"32581359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular source of compensatory ligand not localized\", \"Physiological consequence of the truncated protein unmeasured\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined S-palmitoylation by ZDHHC6 as a localization switch confining FLT3-ITD to the ER and restricting output to STAT5, with loss redirecting it to the plasma membrane and rewiring to AKT/ERK.\",\n      \"evidence\": \"Palmitoylation assay, ZDHHC6 knockdown/overexpression, fractionation, signaling analysis and xenotransplant models with primary AML samples\",\n      \"pmids\": [\"34111291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Depalmitoylase counter-enzyme not identified\", \"Therapeutic exploitability not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapped a BCL-2-family rewiring after FLT3 inhibition in which BCL-2 sequesters BIM, providing a mechanistic rationale for combining FLT3 TKI with venetoclax.\",\n      \"evidence\": \"Reciprocal co-IP of BIM with BCL-2/MCL-1/BAX and apoptosis assays in FLT3-ITD cell lines and primary AML\",\n      \"pmids\": [\"34024909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional vs post-translational basis of BIM shift not separated\", \"Clinical durability not addressed by mechanism\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified DOCK2 as a FLT3-associated Rho-GEF required for proliferation of FLT3-overactive leukemia and modulating TKI/cytarabine sensitivity, expanding the FLT3 interactome.\",\n      \"evidence\": \"MS interaction screen, co-IP, shRNA knockdown with proliferation/colony assays and xenograft survival\",\n      \"pmids\": [\"27748370\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directness of FLT3-DOCK2 binding vs complex association not resolved\", \"Rho-GTPase effector downstream of DOCK2 not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the distinct post-translational layers (palmitoylation, arginine methylation, phosphorylation) and transcriptional cooperators are integrated to select STAT5 versus AKT/ERK outputs and enforce differentiation block remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model linking localization, PTMs and effector choice\", \"Readers/erasers of methyl and acyl marks not fully identified\", \"Structural basis of ITD-driven ligand-independent dimerization undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 12]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 12]},\n      {\"term_id\": \"GO:0004714\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 5, 14]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 8, 9, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 13, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 10, 13]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 13, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FLT3LG\", \"PLCG1\", \"PIK3R1\", \"SHC1\", \"GRB2\", \"CBL\", \"DOCK2\", \"PRMT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}